KRW 5590.0
(-3.79%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 41.62 Billion KRW | -9.08% |
2022 | 41.71 Billion KRW | -23.63% |
2021 | 54.62 Billion KRW | 2.65% |
2020 | 53.21 Billion KRW | 1.98% |
2019 | 52.18 Billion KRW | 10.94% |
2018 | 47.03 Billion KRW | 7.14% |
2017 | 43.9 Billion KRW | 19.88% |
2016 | 36.62 Billion KRW | 59.28% |
2015 | 22.99 Billion KRW | 0.0% |
2012 | 7.07 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 5.36 Billion KRW | -52.25% |
2024 Q1 | 11.23 Billion KRW | 515.08% |
2023 Q2 | 11.1 Billion KRW | 5.84% |
2023 FY | 37.93 Billion KRW | -9.08% |
2023 Q4 | 1.82 Billion KRW | -87.45% |
2023 Q3 | 14.55 Billion KRW | 31.04% |
2023 Q1 | 10.49 Billion KRW | -19.21% |
2022 Q4 | 12.99 Billion KRW | 63.86% |
2022 FY | 41.71 Billion KRW | -23.63% |
2022 Q1 | 9.67 Billion KRW | -31.48% |
2022 Q3 | 7.92 Billion KRW | -7.85% |
2022 Q2 | 8.6 Billion KRW | -11.03% |
2021 Q1 | 18.8 Billion KRW | 47.9% |
2021 FY | 54.62 Billion KRW | 2.65% |
2021 Q2 | 11.69 Billion KRW | -37.8% |
2021 Q3 | 7.63 Billion KRW | -34.69% |
2021 Q4 | 14.11 Billion KRW | 84.77% |
2020 Q3 | 34.82 Billion KRW | 382.04% |
2020 FY | 53.21 Billion KRW | 1.98% |
2020 Q2 | 7.22 Billion KRW | -63.63% |
2020 Q4 | 12.71 Billion KRW | -63.49% |
2020 Q1 | 19.86 Billion KRW | 23.7% |
2019 Q2 | 15.29 Billion KRW | -49.18% |
2019 FY | 52.18 Billion KRW | 10.94% |
2019 Q4 | 16.05 Billion KRW | -13.36% |
2019 Q3 | 18.53 Billion KRW | 21.19% |
2019 Q1 | 30.09 Billion KRW | 0.0% |
2018 FY | 47.03 Billion KRW | 7.14% |
2017 FY | 43.9 Billion KRW | 19.88% |
2016 FY | 36.62 Billion KRW | 59.28% |
2015 FY | 22.99 Billion KRW | 0.0% |
2013 Q3 | 2.21 Billion KRW | 0.0% |
2012 Q3 | 1.1 Billion KRW | 0.0% |
2012 FY | 7.07 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
HLB Co., Ltd. | 109.98 Billion KRW | 62.152% |
iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -430.579% |
BINEX Co., Ltd. | 55.67 Billion KRW | 25.231% |
Bioneer Corporation | 204.55 Billion KRW | 79.65% |
Anterogen.Co.,Ltd. | 7.74 Billion KRW | -437.821% |
MEDIPOST Co., Ltd. | 65.31 Billion KRW | 36.265% |
CrystalGenomics, Inc. | 32.36 Billion KRW | -28.602% |
Helixmith Co., Ltd | 37.36 Billion KRW | -11.403% |
Chabiotech Co.,Ltd. | 285.93 Billion KRW | 85.442% |
Medy-Tox Inc. | 110.88 Billion KRW | 62.458% |
Peptron, Inc. | 16.65 Billion KRW | -149.921% |
Amicogen, Inc. | 52.82 Billion KRW | 21.193% |
HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -157.498% |
LegoChem Biosciences, Inc. | 98.61 Billion KRW | 57.789% |
ALTEOGEN Inc. | 40.93 Billion KRW | -1.693% |
PharmaResearch Co., Ltd. | 89.44 Billion KRW | 53.457% |
SillaJen, Inc. | 5.11 Billion KRW | -714.286% |
JETEMA, Co., Ltd. | 25.66 Billion KRW | -62.203% |
OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -18.096% |
Genomictree Inc. | 16.26 Billion KRW | -155.94% |
MedPacto, Inc. | 26.91 Billion KRW | -54.641% |
D&D Pharmatech | 32.16 Billion KRW | -29.428% |
EASY BIO,Inc. | 29.67 Billion KRW | -40.295% |
GI Innovation, Inc. | 57.59 Billion KRW | 27.72% |